Centessa Pharmaceuticals(CNTA) - 2023 Q4 - Annual Results

Exhibit 99.1 • Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024 • LockBody Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors ® "This is an exciting and pivotal time for Centessa," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "We are laser focused on executing the PRESent registrational studies for SerpinPC, a ...